Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2035 • ACR Convergence 2025
Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatologic Disease
Joshua Friedman¹, JD Lu², Bing Wang², Kinjal Hew², Preeyam Patel², Michael Kennedy², Mark Rose², Curtis Sheldon², Rachel McLean², Emily Svejnoha², MiRa Huyghe¹, Brian Connolly² and Deanna Nguyen², ¹Spyre Therapeutics, Waltham, MA, ²Spyre Therapeutics, Waltham
Background/Purpose: TL1A is an inflammatory cytokine and a member of the TNF superfamily. Target cells that express DR3 and respond to TL1A include T cells,…
Abstract Number: 1445 • ACR Convergence 2025
Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
Jessica A. Walsh¹, Abhijeet Danve², Isabel Truman³, Dan Twigg³, Hervé Besson⁴ and Helena Roque⁵, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, ³Adelphi Real World, Bollington, United Kingdom, ⁴UCB, Breda, Netherlands, ⁵UCB, Brussels, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition affecting the sacroiliac joints and spine.1 Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits…
Abstract Number: 0570 • ACR Convergence 2025
Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Gilad Halpert¹, Eri Govrin¹, Omer Gendelman¹, Abdulla Watad², Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: A substantial number of patients with rheumatic inflammatory/autoimmune diseases, do not achieve adequate symptom control with current standard-of-care therapies, including biologics. The endocannabinoid system…
Abstract Number: 0524 • ACR Convergence 2025
Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors
Esra Erpek¹, Hasan Kocaayan², Elif Ediboğlu³, Ayberk Sinci⁴, Özgür Tosun⁴, Dilek Solmaz³ and Servet Akar⁵, ¹İzmir Katip Çelebi Üniversitesi, Romatoloji Bilim Dalı, İzmir, Izmir, Turkey, ²Izmir Katip Çelebi University School of Medicine, Rheumatology, Turkey, İzmir, Turkey, ³Izmir Katip Çelebi University School of Medicine, Rheumatology, Turkey, İzmir, Izmir, Turkey, ⁴İzmir Katip Çelebi Üniversitesi, Radyoloji Bilim Dalı, İzmir, Izmir, Turkey, ⁵Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey
Background/Purpose: This study aimed to assess the rate of progression in sacroiliac joints in non-radiographic axial spondyloarthritis (nr-axSpA) and to identify the predictive factors for…
Abstract Number: 2376 • ACR Convergence 2025
Efficacy And Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis Stratified by Disease Course: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 2/3 Trial
XiaoFei Shi, Liqing Zhou and He Zhang, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China (People's Republic)
Background/Purpose: Vunakizumab, also known as SHR-1314, is a novel a recombinant humanized monoclonal antibody against interleukin-17A. A randomised, double-blind, phase 2/3 trial (NCT04840485) demonstrated a…
Abstract Number: 2021 • ACR Convergence 2025
Can Colchicine Be a Therapeutic Option for Patients with Ankylosing Spondylitis?
Muhammed Bahaddin Ates¹ and serdal Ugurlu², ¹Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Ankylosing Spondylitis (AS) is a subtype of spondyloarthritis (SpA), a group of inflammatory diseases. AS is influenced by a complex interplay of factors arising…
Abstract Number: 1441 • ACR Convergence 2025
Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Hongbin Li¹ and Huilin Li², ¹Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Nei Mongol, China (People's Republic), ²Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic)
Background/Purpose: Vunakizumab, a humanized anti-interleukin-17A monoclonal antibody, has shown significant efficacy and favorable safety in patients with active ankylosing spondylitis (AS), leading to its approval…
Abstract Number: 0569 • ACR Convergence 2025
ASAS recommendations on reporting outcomes of core outcome set instruments in axial spondyloarthritis clinical trials
Floris A. van Gaalen¹, Victoria Navarro-Compan², Xenofon Baraliakos³, Filip Van den Bosch⁴, Lianne S. Gensler⁵, Ihsane Hmamouchi⁶, Robert Landewé⁷, Pedro Machado⁸, Helena Marzo-Ortega⁹, Valeria Rios Rodriguez¹⁰, Denis Poddubnyy¹¹, Sofia Ramiro¹² and Désirée Van Der Heijde¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco, ⁷Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁸Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁹NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹⁰Charité-Universitétsmedizin Berlin, corporate member of Freie universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ¹¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹²Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The recently updated Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS)includes an agreed minimum set of instruments that should be used in…
Abstract Number: 0475 • ACR Convergence 2025
Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
Cristiano Moura¹, Luck Lukusa², Denis Choquette³, Gilles Boire⁴, Nathalie Carrier⁵, Autumn Neville² and Sasha Bernatsky⁶, ¹Research Institute of the McGill University Health Center, Montréal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, Canada, ³Institut de Rhumatologie de Montréal, Saint-Donat-de-Montcalm, Canada, ⁴Retired, Sherbrooke, QC, Canada, ⁵Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In April 2022, the Canadian province of Quebec introduced a mandatory non-medical switch to biosimilars for persons on bio-originators to manage healthcare costs. Our…
Abstract Number: 2360 • ACR Convergence 2025
Treatment adherence in ankylosing spondylitis: A comparison of TNFi, IL-17i, and JAKi using real-world data
Marina Magrey¹ and Jennifer Murphy², ¹Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ²University Hospitals, Cleveland Medical Center, cleveland, OH
Background/Purpose: Treatment adherence is essential for achieving sustained disease control and improving outcomes in patients with ankylosing spondylitis (AS). This study aimed to evaluate real-world…
Abstract Number: 1984 • ACR Convergence 2025
Improving Lipid Screening Rates in Rheumatic Disease Patients: An Academic Fellowship Quality Improvement Project
Mahnoor Javed¹, Deepak Jagannath², Lilly Morgan¹, Rishi Patel¹, Eleonora Avenatti¹, Kanika Monga¹ and Kenneth Williams¹, ¹Houston Methodist, Houston, ²Houston Methodist Hospital, Sugar Land, TX
Background/Purpose: Autoimmune diseases, including rheumatoid arthritis (RA) and spondyloarthritis (SpA)—which encompasses ankylosing spondylitis (AS) and psoriatic arthritis (PsA)—are associated with chronic inflammation and increased cardiovascular…
Abstract Number: 1440 • ACR Convergence 2025
Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis
MÜSLÜM FIRAT İKİKARDEŞ¹, EMRAH KOÇ¹, gEZMIS KIMYON², EMİNE DUYGU ERSOZLU¹ and TAYYIBE SALER¹, ¹ADANA SEHİR HASTANESİ, ADANA, Turkey, ²MUSTAFA KEMAL UNIVERSITY, HATAY, Turkey
Background/Purpose: We aimed to compare the demographic and clinical characteristics of the patients with axial spondyloarthritis (aSpA) receiving standard-dose versus tapered-dose biologic disease-modifying antirheumatic drugs…
Abstract Number: 0560 • ACR Convergence 2025
Single Cell Sequencing Analysis of Tumour Necrosis Factor Inhibitor Drug Response Reveals Enrichment of Pro-inflammatory Pathway in Non-responders and Amino Acid Metabolic Pathways in Responders
Ayantika Talukdar¹, Phuong Nguyen², Neke Ibeke³, Rohan Machhar¹, Mansi Aparnathi¹, Archita Srinath², Akihiro Nakamura⁴, Robert Inman³, Igor Jurisica⁵, Proton Rahman⁶, Nigil Haroon⁷ and Sareh Keshavarazi¹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Queen's University, Kingston, ON, Canada, ⁵University Health Network, Toronto, Canada, ⁶Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁷Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Ankylosing Spondylitis (AS) is a type of chronic inflammatory arthritis affecting the spine and peripheral joints. Although tumor necrosis factor inhibitors (TNFi) substantially improve…
Abstract Number: 0214 • ACR Convergence 2025
Systematic Comorbidity Screening in Inflammatory Arthritis: The Experience of a Tertiary-Care Centre
Camille Bourgeois¹, Alexandra Kobza², Olivier Fogel³, Maxime Dougados⁴ and Anna Molto⁵, ¹Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ²University of Calgary, North Vancouver, BC, Canada, ³AP-HP, Paris, France, ⁴Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ⁵Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), are at elevated risk for comorbidities, complicating disease management. Despite rheumatology societies…
Abstract Number: 2361 • ACR Convergence 2025
Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis
Mark Hwang¹, Seokhun Kim², Shervin Assassi³, Joyce Samuel¹, Charles Green¹, Jon Tyson² and John Reveille⁴, ¹UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁴Department of Medicine, University of Texas Medical Center, Houston, TX
Background/Purpose: We previously reported primary outcomes from a Bayesian series of N-of-1 trials comparing celecoxib, meloxicam, and naproxen in axial spondyloarthritis (axSpA), demonstrating improved ASDAS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].